首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名:Signal transduction and targeted therapy

缩写:

ISSN:2095-9907

e-ISSN:2059-3635

IF/分区:40.8/Q1

文章目录 更多期刊信息

共收录本刊相关文章索引2292
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
Chen Xue,Qingfei Chu,Qingmiao Shi et al. Chen Xue et al.
The Wnt signaling pathway is critically involved in orchestrating cellular functions such as proliferation, migration, survival, and cell fate determination during development. Given its pivotal role in cellular communication, aberrant Wnt ...
Dan Liu,Xue Wang,Yuheng Han et al. Dan Liu et al.
Donor selection determines the occurrence of acute graft-versus-host-disease (aGVHD) following allogeneic hematopoietic stem cell transplantation (allo-HSCT). To optimize the current clinical donor selection criteria and identify putative d...
Yeyu Cai,Tian Chai,William Nguyen et al. Yeyu Cai et al.
Phototherapy has emerged as a promising modality in cancer treatment, garnering considerable attention for its minimal side effects, exceptional spatial selectivity, and optimal preservation of normal tissue function. This innovative approa...
Jun Ma,Xiangyu Yang,Yanan Li et al. Jun Ma et al.
Arterial stiffness is a critical factor in cardiovascular and cerebrovascular events, yet clinical practice lacks specific therapeutic targets and biomarkers for its assessment. Hyperlipidemia closely correlates with arterial stiffness, and...
Xiaoming Liang,Yanan Zhou,Yun Yang et al. Xiaoming Liang et al.
With the broad spread of the chikungunya virus (CHIKV), there is an increasing demand for more effective and broadly protective vaccines. Here, we designed CHIKV mRNA vaccines containing full-length structural proteins or part of structural...
Chao Liu,Lisha Sun,Nan Niu et al. Chao Liu et al.
Significant heterogeneity exists in hormone receptor (HR)-positive/HER2-positive (HR+/HER2+) breast cancer, contributing to suboptimal pathological complete response rates with conventional neoadjuvant treatment regimens. Overcoming this ch...